109TH CONGRESS 1ST SESSION

H. R. 3550

To amend the Public Health Service Act to improve provisions relating to Parkinson's disease research.

IN THE HOUSE OF REPRESENTATIVES

July 28, 2005

Mr. EVANS (for himself, Mrs. Maloney, Mr. Udall of Colorado, and Mr. Boehlert) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Public Health Service Act to improve provisions relating to Parkinson's disease research.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE.
- 4 This Act may be cited as the "Morris K. Udall Par-
- 5 kinson's Disease Research Act Amendments of 2005".
- 6 SEC. 2. MORRIS K. UDALL PARKINSON'S DISEASE RE-
- 7 SEARCH ACT OF 1997.
- 8 (a) FINDINGS.—Subsection (b) of section 603 of the
- 9 Morris K. Udall Parkinson's Disease Research Act of
- 10 1997 (42 U.S.C. 284f note) is amended—

1 (1) in the subsection heading by striking 2 "FINDING" and inserting "FINDINGS"; and (2) by striking paragraph (1) and inserting the 3 4 following: "(1) FINDINGS.—Congress finds the following: 5 6 "(A) To take full advantage of the tremen-7 dous potential for finding a cure or effective 8 treatment, the Federal investment in Parkin-9 son's must be expanded, as well as the coordi-

tutes of Health research institutes.

"(B) The National Institutes of Health should invest in national health priorities focusing on those with the greatest expense to society or research with positive, translational, and measurable outcomes. Parkinson's research, with its clear potential for translating basic research into clinical results applicable to a wide array of disorders, is a prime example of research that fulfills the National Institutes of Health's national health priority criteria, including the high expense to society."

nation strengthened among the National Insti-

23 (b) Public Health Service Act.—Section 409B 24 of the Public Health Service Act (42 U.S.C. 284f) is 25 amended—

10

11

12

13

14

15

16

17

18

19

20

21

22

1 (1) in subsection (b), by striking paragraph (2) 2 and inserting the following:

"(2) Conference.—

"(A) IN GENERAL.—The Director of NIH shall convene a coordinating and planning conference every 2 years with relevant institutes and non-governmental organizations to conduct a thorough investigation of all Parkinson's research that is funded in whole or in part by the National Institutes of Health and to identify shortcomings and opportunities for more effective treatments and a cure for Parkinson's disease. The Director shall report to Congress on the coordination among the institutes in carrying out such research.

"(B) Research investment plan.—

"(i) IN GENERAL.—The results of each conference convened under subparagraph (A) shall be included in a research investment plan that provides for measurable results with the goals of better treatments and a cure for Parkinson's disease being the determining factors in the allocation of Parkinson's disease research dollars. The plan shall include an outline of

the manner in which to fully utilize the Udall Center program to ensure the continuation of a particular focus on translational research, including a clinical component.

"(ii) Budget and implementation strategy.—The plan submitted under clause (i) shall include a budget (that includes both programmatic and dollar line items) and implementation strategy (that incorporates the use of special initiatives such as requests for applications, program announcements with set-asides, or similar directed research mechanisms) together with results to be reported back to Congress.

"(C) Submissions to congress.—The plan under subparagraph (B) (including the budget and implementation strategy) and the expected results of plan implementation shall be submitted to Congress not later than 3 months after the conference is convened under subparagraph (A). Reports on the outcomes of the plan, including actual spending and actual results,

1	shall be submitted to Congress on an annual
2	basis.
3	"(D) Funding.—The Secretary shall en-
4	sure that adequate funding is available under
5	this section to carry out the activities described
6	in the investment plan under subparagraph
7	(B).";
8	(2) in subsection (c)—
9	(A) in paragraph (1)—
10	(i) by striking "not more than 10";
11	and
12	(ii) by adding at the end the fol-
13	lowing: "The Director shall ensure that an
14	additional center shall be funded under
15	this paragraph to serve as the coordinating
16	center to coordinate the activities con-
17	ducted by each of the centers funded under
18	this paragraph to further focus and man-
19	age the interdisciplinary efforts of such
20	centers.";
21	(B) in paragraph (2)(A)(ii), by striking
22	"conduct basic and clinical research" and in-
23	serting "in carrying out research, ensure that a
24	significant clinical component is provided for in
25	addition to ongoing basic research"; and

1	(C) by adding at the end the following:
2	"(5) Review process.—The Director of NIH
3	shall establish a review process with respect to appli-
4	cations received for grants under paragraph (1).
5	Such process shall provide for the evaluation of ap-
6	plicants in a manner that recognizes the unique as-
7	pects of the clinical, coordination, and multidisci-
8	plinary components of the applicants.";
9	(3) in subsection (d)—
10	(A) by striking "is authorized to establish
11	a grant program" and inserting "shall award
12	grants"; and
13	(B) by inserting before the period at the
14	end the following: "and shall be awarded in a
15	manner consistent with the research investment
16	plan under subsection (b)(2)(B)"; and
17	(4) by striking subsection (e) and inserting the
18	following:
19	"(e) Report.—The Director of NIH, in consultation
20	with the Director of the Centers for Disease Control and
21	Prevention, shall conduct an investigation, and prepare
22	and submit to the appropriate committees of Congress a
23	report, on the incidence of Parkinson's disease, including
24	age, occupation, and geographic population clusters, and
25	related environmental factors relating to such disease.

- 1 "(f) Authorization of Appropriations.— For
- 2 the purpose of carrying out this section, and section 301
- 3 and this title with respect to research focused on Parkin-
- 4 son's disease, there are authorized to be appropriated up
- 5 to \$100,000,000 for fiscal year 1998, such sums as may
- 6 be necessary for each of the fiscal years 1999 and 2000,
- 7 and such sums as may be necessary for fiscal years 2006
- 8 and each subsequent fiscal year.".

 \bigcirc